What is Botulax Made Of | Active Ingredient, Formulation, and Purity

Observation of State

In its unopened state, a very thin layer of white or off-white lyophilized powder is present at the bottom of the Botulax. This physical form is created through a vacuum freeze-drying process at -40°C to -50°C. For a 100-unit (100U) specification, the total weight of all solid components inside is only 1.4 mg, which includes 0.5 mg of human serum albumin and 0.9 mg of sodium chloride. Since the mass of the active ingredient, type A botulinum toxin, is only about 4.8 nanograms, it is completely invisible to the naked eye. The white substance users see is mainly the auxiliary excipients acting as a support structure.

• Appearance of the Cake: The powder in the dry state should appear as a complete disc or cracked thin flakes, with a pure white color. If the powder is observed to turn yellow, clump, or show obvious deliquescence, it indicates that the moisture content in the may have exceeded the 3% standard limit, which causes irreversible degradation of protein molecules.
• Container Specification: Borosilicate transparent glass complying with USP Type I standards are used. This material has an extremely low alkali metal release rate, preventing any impact on the pH of the drug solution during its 36-month shelf life.
• Sealing Structure: The mouth is sealed with a medical-grade butyl rubber stopper, covered with an aluminum-plastic combination cap with anti-tamper markings. This three-layer sealing structure ensures that a constant vacuum negative pressure state is maintained inside the over the long term.

When injecting 0.9% sodium chloride injection into the, because a pressure difference of about 500 to 600 mmHg is maintained inside, the diluent will be automatically sucked into the the moment the pierces the rubber stopper. If the liquid does not enter automatically but requires pressure to be injected, it indicates that the packaging has lost its vacuum. Loss of vacuum is usually caused by stopper aging or micro-cracks in the body. As moisture and oxygen from the air enter, the nanogram-level toxin protein inside the will oxidize or hydrolyze within hours, leading to a significant drop in clinical potency.

• Automatic Suction Speed: When using a 21G for dilution, 1.0 ml of physiological saline should complete automatic suction within 1 to 2 seconds, proving the standard nature of the internal pressure.
• Bubble Observation: After injecting the liquid, a small amount of fine bubbles may be generated in the due to the liquid jet and the surface activity of the albumin. These bubbles will naturally dissipate after standing for 30 to 60 seconds.
• Dissolution Clarity: The reconstituted solution should be a completely transparent, colorless liquid without any visible suspended matter. According to pharmacopoeia standards, its turbidity test value should be below 3 units (NTU).

After the dilution operation is completed, observing the fluid characteristics of the solution is also part of assessing the formulation state. The viscosity of Botulax after reconstitution is close to that of physiological saline, approximately 1.0 to 1.1 mPa·s. This low-viscosity characteristic allows doctors to use extremely fine 30G or 32G for injection, and the injection pressure is evenly distributed. If the reconstituted liquid appears cloudy, precipitated, or shows a stringy phenomenon, it indicates that the albumin has denatured or proteins have aggregated. Such physical abnormalities signal a loss of potency, and it should no longer be used clinically.

• Reconstitution Volume Reference: Depending on clinical needs, 1.0 ml, 2.0 ml, or 2.5 ml of diluent is usually recommended for each 100U of Botulax, corresponding to toxin concentrations of 10U/0.1ml, 5U/0.1ml, or 4U/0.1ml, respectively.
• Liquid Level Height: After adding 1.0 ml of diluent, the liquid level in the is typically at about one-fifth of the lower part of the body. Since the walls are treated with a hydrophobic coating, the drug solution will not stick to the neck area, ensuring precise extraction volume.
• pH Monitoring: The pH of a standard reconstituted solution is stable between 6.0 and 7.0. Within this range, the 900 kDa protein complex is in an electrically neutral or weakly charged state, showing the strongest chemical resistance.

The cake should maintain a stable volume in a dark environment at 2°C to 8°C. If the storage environment humidity is too high or the seal is damaged, the white powder will begin to shrink from the edges of the wall. Experimental data shows that when the cake volume shrinks by more than 50%, the rate of protein disulfide bond breakage due to residual moisture will accelerate by 5 to 10 times. Therefore, before each preparation, the distribution state of the powder at the bottom of the must be observed by rotating the. High-quality Botulax powder should not flow like a liquid when rotated but should maintain a fixed attached form.

This observation mechanism is not only a re-verification of product quality but also a basic guarantee for clinical safety. Since the biological activity of botulinum toxin depends entirely on its complex tertiary and quaternary protein structures, any minor visual deviation—such as a change in color, a slowing of dissolution speed, or a loss of vacuum—corresponds to molecular failure. In a standard medical environment, the stability of these physical characteristics ensures that each can provide consistent neuromuscular blockade intensity throughout its 36-month shelf life.

Since no chemical preservatives (such as benzyl alcohol) are added to the formula, the reconstituted liquid faces the dual risks of microbial invasion and natural protein degradation. It is recommended to use it within 24 hours after reconstitution. Within this time window, the solution maintains high transparency and chemical stability. If the reconstituted drug solution is left for more than 48 hours, the solution may appear slightly milky due to the slow denaturation of albumin. Even if the difference seems minimal to the naked eye, the internal toxin potency may have already decreased by 15% to 20%.

Purity

Botulax retains the 900 kDa complex after purification, with the main component being the 150 kDa active neurotoxin. Its protein load is extremely low, and the residual impurity amount per is controlled at the nanogram level. Laboratory tests show that its specific activity remains above 20U/ng. This purity standard supports its 36-month shelf life when stored at 2°C-8°C, and the proportion of neutralizing antibodies produced after multiple uses is less than 1%.

Protein Load Distribution

The Botulax 100U formulation primarily consists of type A botulinum toxin complex, human serum albumin (HSA), and sodium chloride. In each 100-unit of the product, the mass distribution of the effective protein complex is extremely low, typically maintained between 4.8 nanograms and 5.2 nanograms. The molecular weight of this complex is 900 kDa, formed by the non-covalent binding of a 150 kDa neurotoxin core and approximately 750 kDa of endogenous accessory proteins. These accessory proteins include hemagglutinin proteins (HA) and non-toxic non-hemagglutinin proteins (NTNH). Laboratories measure via high-purity chromatographic analysis that Botulax’s specific activity reaches 20U/ng to 25U/ng, a value reflecting the number of units that can produce biological effects per nanogram of protein. To maintain the stability of the toxin on the glass wall and prevent molecular denaturation, 0.5 mg (500,000 nanograms) of human serum albumin is added to the formula. From a ratio perspective, the mass ratio of protective protein to toxin protein is approximately 100,000:1. The table below shows the precise mass distribution and corresponding biochemical functions of the Botulax 100U bottled formulation:

During the manufacturing phase, Hugel uses multistage SEC-HPLC (Size Exclusion High-Performance Liquid Chromatography) to monitor the protein load distribution. Analysis shows that the purity of Botulax’s 900 kDa complex exceeds 98%, and the proportion of free 150 kDa core toxin in the formulation is minimal. This highly concentrated protein distribution can reduce molecular diffusion after injection. Experimental data shows that the diffusion radius of the 900 kDa macromolecular structure in tissue is more than 15% smaller than that of the 150 kDa purified toxin. There is a direct link between the size of the protein load and the frequency of neutralizing antibody production. Clinical immunology studies point out that when the non-functional protein load in botulinum toxin exceeds a certain threshold, the human immune system identifies it as a foreign body. Botulax controls the total protein amount per 100 units to around 5 nanograms, a level below the threshold for triggering a large-scale immune response. Based on serum sampling of 485 subjects who used Botulax for more than 12 months, the neutralizing antibody conversion rate was below 0.2%. The following is a comparative analysis of protein load data for different brands of botulinum toxin:

In-depth analysis of Botulax using liquid chromatography-tandem mass spectrometry (LC-MS/MS) reveals a very constant distribution ratio of HA-33 and HA-17 among the accessory proteins. The presence of HA proteins is not only for structural support but also assists toxin molecules in crossing intestinal epithelial or other biological membrane barriers. Within 24 to 72 hours after clinical injection, the 900 kDa protein complex gradually dissociates as the local pH changes (shifting from neutral to slightly alkaline), releasing 150 kDa active heavy and light chains. The source of human serum albumin in the formulation has undergone strict virus inactivation treatments, complying with USP and EP standards. Although albumin accounts for the vast majority of the mass in the, its physical distribution is uniformly dispersed. Under a scanning electron microscope (SEM), the lyophilized Botulax shows a honeycomb-like albumin scaffold, with botulinum toxin molecules adsorbed onto the surface of these scaffolds. After being placed at 37 degrees Celsius for 14 days, the protein degradation rate of Botulax is below 3%, and the potency remains above 95% of the nominal value. For medical institutions with high-frequency use, this stable protein load distribution ensures consistency of effect between different batches. Statistical analysis shows that the coefficient of variation (CV) for protein content between different production batches of Botulax is less than 5%.

Reducing Antibody Generation

The Botulax 100U formulation strictly limits the total protein load per to 4.8 nanograms to 5.2 nanograms through a multistage chromatographic purification process. The human immune system has the ability to recognize foreign proteins. When botulinum toxin is injected into tissue, the inactive proteins it carries act as antigens to induce B lymphocytes to produce antibodies. The 900 kDa complex selected for Botulax contains the 150 kDa neurotoxin core and surrounding accessory proteins, a structure that protects the active part from protease degradation in a physiological pH environment. Laboratory data shows that Botulax’s specific activity is maintained above 20U/ng. High specific activity means less total protein mass is required to produce the same clinical effect, thereby reducing the opportunity for the immune system to be exposed to foreign proteins at the source. If the protein content in the formulation is too high or if there are a large number of denatured proteins, lymphocytes will display antigen peptides through MHC-II molecules, leading to the production of neutralizing antibodies (NAb). The production of neutralizing antibodies leads to “secondary failure” of clinical treatment, where the muscle relaxation effect gradually weakens or completely disappears after multiple injections. During the development phase, Botulax conducted a 24-month serological follow-up on 450 long-term users, with tests performed via mouse neutralization assay (MPA) and enzyme-linked immunosorbent assay (ELISA). Data showed that the neutralizing antibody conversion rate in subjects was below 0.15%, primarily due to the efficient removal of impurity proteins during production. The accessory proteins in the formulation mainly include HA-33, HA-17, and NTNH proteins, with their distribution ratios in Botulax precisely calculated to ensure structural integrity during storage. Impure formulations often contain protein fragments caused by freeze-drying pressure. These fragments no longer have biological activity but still retain immunogenicity, making them easy for macrophages to engulf and activate an immune response. The vacuum drying technology used in Botulax reduces physical shear damage to protein molecules, keeping the proportion of effective active protein in the finished product above 98%.

• Total Protein Mass Limitation: The 100U specification product contains only about 5 ng of toxin complex protein, reducing the probability of immune recognition.
• Neutralizing Antibody Incidence: Multiple clinical follow-up records show its immunological safety during long-term use, with conversion values far below industry warning lines.
• Chromatographic Testing Standards: HPLC is used to monitor the protein purity of each batch, ensuring no bacterial culture medium residues.
• Specific Activity Index: The 20U/ng parameter supports doctors in using smaller physical doses to achieve the expected depth of muscle blockade.

Pharmacokinetic studies suggest that the interval between two injections of Botulax should be no less than 90 days, and the total dose for a single injection is recommended to be within the 200U to 300U range. As the single-use dose increases, the number of protein molecules entering the circulatory system increases linearly. The low-protein design of Botulax allows patients’ cumulative protein exposure to remain within safe thresholds even when receiving larger doses for masseter or calf muscle treatments. The table below details the immune risk prediction data for Botulax under different dose exposures:

At the biochemical level, the 150 kDa neurotoxin core consists of a 100 kDa heavy chain and a 50 kDa light chain. The heavy chain is responsible for finding and binding to receptors on the surface of nerve endings, while the light chain enters the cell to exert its pharmacological effect. If antibodies bind to the receptor-binding region of the heavy chain, they block the toxin from entering the nerve cell. Botulax’s production process protects the natural conformation of the heavy chain terminal, reducing the exposure of abnormal epitopes due to incorrect molecular folding. In long-term observation of subjects, medical teams found that even for patients who used it for more than 10 cycles, their clinical performance (such as wrinkle smoothing and muscle thickness reduction) deviated by only 3%-5% compared to the initial cycles. The 0.5 mg of human serum albumin added to the formulation also acts as an immune buffer. As a stabilizer, albumin can encapsulate small amounts of botulinum toxin molecules, reducing their surface area directly exposed to immune cells. This molecular-level embedding further enhances the product’s safety. In addition, the production environment for Botulax follows international biopharmaceutical standards, removing endotoxins that could induce non-specific immune responses. The measured endotoxin content is below 0.5 EU/.

Batch Stability Testing

Laboratory technicians randomly select a fixed proportion of samples from every ten thousand and compare their biological activity after dilution. Although international pharmacopoeias allow the potency of botulinum toxin to fluctuate between 80% and 125% of the nominal value, Botulax’s internal controlled standards compress this error range to within +/- 5U to 10U. This control over narrow fluctuations allows clinicians to switch between different batches of the product without recalculating the injection dose to achieve the expected depth of muscle blockade. Statistical data shows that the potency coefficient of variation (CV) for 50 consecutive production batches of Botulax remains consistently below 4.5%.

The quality control department issues a Certificate of Analysis (CoA) for each batch, covering more than 20 monitoring data points from raw material input to final sealing, ensuring that the physical and chemical indicators of every milligram of formulation meet USP specifications.

The production line uses vacuum drying technology to convert the liquid into powder. If residual moisture exceeds 3.0%, protein molecules will aggregate or degrade, causing the product to fail prematurely during its shelf life. Botulax’s laboratory testing data shows that the average moisture content of its finished products is typically maintained between 1.2% and 1.8%. Furthermore, the vacuum level inside the is also a mandatory inspection item; technicians use electronic leak detectors for non-destructive testing of every. If the vacuum environment is compromised during transportation or storage, oxygen entering the will cause the 150 kDa neurotoxin core to oxidize and denature rapidly. Experiments have proven that while maintaining a complete vacuum, the biological activity of Botulax in a 2°C to 8°C environment can remain stable for more than 36 months, with the potency decline rate being less than 2% per year.

Molecular integrity testing for the 900 kDa complex is completed via SEC-HPLC technology, which can precisely identify whether there are protein fragments, thereby avoiding immune risks caused by damaged proteins.

Chromatographic analysis (SEC-HPLC) is an important means of monitoring purity. Through molecular exclusion technology, the laboratory can clearly observe the peak distribution of the 900 kDa complex. If impurity peaks appear at non-predetermined positions in the chromatogram, it indicates bacterial residues or protein denaturation during the purification process for that batch, and such batches are automatically rejected by the system. In addition to the main toxin protein, the 0.5 mg of human serum albumin added to the formulation must also undergo purity verification to ensure it does not contain any known blood-borne pathogens. pH testing is also part of stability testing, with the pH of reconstituted Botulax strictly locked between 6.0 and 7.0. This pH range not only maintains the charge balance of the toxin molecules but also reduces stinging pain at the injection site. The pH fluctuation between different batches is minimal, with batch-to-batch deviations measured by the laboratory typically not exceeding 0.15 units.

Real-time stability testing and accelerated stability testing are conducted in both directions, with the latter requiring the product to be placed in a 37-degree Celsius incubator for 14 days, after which the activity retention rate must be higher than 95%.

Laboratories use the Limulus Amebocyte Lysate (LAL) test for pyrogen detection on each batch, with Botulax’s endotoxin levels controlled below 0.5 EU per. This value is far below the threshold for triggering a systemic fever response clinically, ensuring biological safety when the product is used for high-dose injections (such as treating muscle spasms). In vibration experiments simulating long-distance transportation, technicians place the product on a vibration table at a specific frequency for 48 hours, followed by observation of the physical properties of the powder and protein stability. Results showed that after this physical stress testing, Botulax’s reconstitution speed remained within 30 seconds, and the solution appeared clear and transparent, with no visible suspended matter or precipitation.

The fully automated production environment reduces human interference, allowing Botulax to exhibit high physical stability across different climate zones globally (such as high-temperature environments in Southeast Asia or low-temperature environments in Northern Europe).

Even if the product experiences repeated fluctuations from refrigeration to room temperature and back, its protein structure can remain stable as long as the temperature does not exceed the specified threshold. In a retrospective study of samples from 12 different production years, researchers found that Botulax produced in earlier years still maintained its potency at around 102U near the end of its shelf life, proving that the production process has shown extremely strong reproducibility over the span of several years.